Skip to main content
Clinical Trials/NCT02500888
NCT02500888
Unknown
Not Applicable

Initial Evaluation of Efficacy and Adverse Events of Single Lesions in Bilateral Ventral-capsular and Ventral Capsulotomy-striatal by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder

Hospital de Clinicas de Porto Alegre1 site in 1 country10 target enrollmentJune 30, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
OCD
Sponsor
Hospital de Clinicas de Porto Alegre
Enrollment
10
Locations
1
Primary Endpoint
Change in OCD symptoms
Last Updated
5 years ago

Overview

Brief Summary

The aim of this study is to evaluate, through a pilot study with about ten cases, if bilateral ventral capsulotomy by linear accelerator enable modification of obsessive-compulsive symptoms and quality of life in patients with severe and refractory obsessive compulsive disorder (OCD) and also investigate possible adverse effects / complications of the procedure.

Detailed Description

About ten patients with severe and refractory OCD will receive bilateral single lesions at the bottom of the anterior limb of the internal capsule by linear accelerator. Prior to the procedure, a detailed clinical and psychiatric evaluation, plus an extensive battery of psychiatric diagnostic tests, severity and progression of OCD, depression / anxiety symptoms, presence of tics, psychosocial impairment, quality of life, familial accommodation and neuropsychological and personality testes will be performed. Furthermore, the patients will be also assessed by serological and neuroimaging tests. The Individuals will be periodically evaluated and followed up for one year. The results of the scores of the rating scales will be analyzed and compared, as well as the profile of adverse events, cognitive or personality changes and improves in clinical tests and neuroimaging studies.

Registry
clinicaltrials.gov
Start Date
June 30, 2015
End Date
June 30, 2022
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • OCD diagnosis, according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a major disease entity. If comorbidity with other psychiatric or personality disorders, OCD symptoms dominate the clinical picture and precede other disorders.
  • Duration of OCD symptoms of at least five years.
  • Scores range of the obsessive-compulsive symptoms "Yale-Brown Obsessive-Compulsive Scale" (YBOCS) greater than 26 (or greater than 13, if obsessions or compulsions alone).
  • Fill up the criteria for refractory to prior treatments.
  • Be accepted by the method of "best estimate" for defining the patient is refractory, which consisted of confirmation by at least two specialists obsessive-compulsive disorder that the patient fulfills the criteria for effective refractory to previous treatments.

Exclusion Criteria

  • History of head trauma or post-traumatic amnesia.
  • Background of systemic or neurological diseases with brain impairment, severe and active.
  • History of current use of substances capable of inducing psychopathological manifestations, or signs of cumulative effects of alcohol or drugs in the central nervous system (such as cortical atrophy), confirmed by neuroimaging.
  • pregnancy or lactation.
  • Refusal to submit to the radiosurgical procedure.
  • Refusal to accept the informed consent form, or participate.
  • History of mental retardation and / or inability to understand the informed consent, confirmed by neuropsychological tests of the initial evaluation.
  • Lack of family or companion with proper capacity of understanding of the informed consent in patients with comorbid major depression or psychosis that could potentially have difficulty performing the appropriate judgment as to participate in the study.

Outcomes

Primary Outcomes

Change in OCD symptoms

Time Frame: Every 3 months until 12 months

Application of Yale-Brown Obsessive-Compulsive Scale (Y-Bocs) scale

Secondary Outcomes

  • Change in brain-derived neurotrophic factor (BDNF) blood dosing(12 months)
  • Change in quality of life.(Every 3 months until 12 months)
  • Side effects and complications(Every 3 months until 12 months)
  • Change in near-infrared spectroscopy (NIRS) brain blood flow(12 months)
  • Change in familial accommodation(Every 3 months until 12 months)
  • Change in depressive symptoms.(Every 3 months until 12 months)
  • Change in psychological tests(12 months)
  • Change in OCD symptoms by NIMH.(Every 3 months)
  • Change in Global Functioning(Every 3 months until 12 months)
  • Change in anxiety symptoms.(Every 3 months until 12 months)
  • Change in OCD symptoms by CPRS(Every 3 months)

Study Sites (1)

Loading locations...

Similar Trials